According to GlobalData’s medical device pipeline database, 69 COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 64 are in active development, while the remaining seven are in an inactive stage of development. There are 16 products in the early stages of development, and the remaining 48 are in the late stages of development.
Multiplex Nucleic Acid Amplification Tests (NAATs), also known as syndromic or respiratory panels, are used to screen different respiratory pathogens DNA in the patient sample. The test targets multiple nucleic acid sequences to amplify and detect several different pathogens from a single sample. One unit refers to one multiplex NAAT test.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) devices. Overall, most of these COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) pipeline devices are being developed by private entities.
Key players involved in the active development of COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) include Luminex, DiaCarta, CoSara Diagnostics, Becton Dickinson and Co, Hologic, MiRXES, Molbio Diagnostics, MultiplexDX, NeuMoDx Molecular and Numentus Technologies.
For a complete picture of the developmental pipeline for COVID-19 Multiplex Nucleic Acid Amplification Tests (NAATs) devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
